Increased Consumption of Antithrombin 111 in Patients Receiving Granulocyte-Macrophage Colony-Stimulating Factor After Bone Marrow Transplantation
To the Editor:
Granulocyte-macrophage colony-stimulating factor (GM-CSF) can activate macrophages to secrete tumor necrosis factor a (TNFa) and interferon y (IFNy). Recombinant TNFa and IFNy are inductors of macrophage procoagulant activity in vitro. ' We analyzed the activation of coagulation and the plasma levels of antithrombin 111 (AT 111) in patients that received either GM-CSF or G-CSF after highdose chemoradiotherapy.
From 1988 to 1993, 30 patients with solid tumors (Ewing's sarcoma, n = 17; neuroblastoma, n = 8; rhabdomyosarcoma, n = 5 : allogenous bone marrow transplantation [BMT] , n = 5; autologous stem cell grafts, n = 25) were treated according to the Hyper-ME 2 C protocol.' Each of the 15 patients received GM-CSF and G-CSF, respectively, from day O until a stable engraftment was achieved. Because there is no sufficient number of patients that received Hyper-ME ? C and no hematopoetic growth factor, we assessed 21 patients with acute lymphoblastic leukemia (ALL) as the best available control group. These control patients underwent allogenous BMT after 12 Gy total body irradiation plus 60 mgkg etoposide' as conditioning therapy. All patients were in complete or very good partial remission.
AT 111 was assessed using the chromogenic substrate S-2238 (Chromogenix, Melndal, Sweden); the results were expressed as percent of pooled normal human plasma (NHP). Plasma prothrombin fragment F1 + 2 and thrombin-AT 111 complexes (TAT) were measured using commercially available enzyme-linked immunosorbent assay systems (Behringwerke AG, Marburg, Germany). All parameters were measured at 3-to 4-day intervals through day +49 after BMT.
Substitution of AT 111 (Atenativ, Kabi, Uppsala, Sweden) was performed when an AT 111 level below 90% of NHP was detected.
The daily dose was calculated as: AT 111 concentrate (IU) = (100 -detected AT 111 level) X kg body weight. When this substitution was insufficient to increase the AT I11 level to greater than 90% NHP, the dose of AT 111 substitution was doubled. In the GM-CSF patients, minimum mean AT 111 levels (80% of NHP) were found from day +4 through day + 18 (P < .05, unpaired t-test when compared with the other patient groups), followed by slow normalization until day +49 (Fig 1) . In contrast, the mean AT For personal use only. on October 26, 2017. by guest www.bloodjournal.org From 0 4 7 1 1 1 4 1 8 2 1 2 5 2 8 3 2 3 5 39 4 2 4 6 4 9 days after bmt 111 levels in the G-CSF patients, and in the patients without growth factor were greater than 90% NHP at any time point through day +49 (Fig l) . In the GM-CSF patients, the mean daily AT Ill substitution was 22 to 37 IU/kg body weight from day +7 through +25, whereas the G-CSF patients and the patients without growth factor received maximum 7 IUikg at day + 1 1 (Fig 2) .
TAT levels, before the first substitution with AT 111, were significantly higher in the GM-CSF group (15.3 -C 5.6 &L; mean 2 SD) than in the G-CSF group (4.5 2 1.8 p g L ; P = .025, unpaired t-test). F1 + 2 levels were normal in both groups. The mean (maximum) length of hematopoetic growth factor infusion was 25 (40) days for G-CSF, and 28 (47) days for GM-CSF (Fig 2) . This analysis shows increased consumption of AT 111 in patients that received GM-CSF compared with those that received G-CSF. The AT III levels and the doses of AT III substitution were similar in patients that received G-CSF and in patients that received neither 3987 growth factor, with respect to the limitation, that patients without growth factors had another underlying disease and conditioning therapy. Activation of the coagulation system is proved by the increased TAT levels.
Indirect evidence for activation of humoral coagulation under GM-CSF was shown by Stephens et a1: who described an increased rate of clots in central venous catheters in patients that received GM-CSF for stem cell apheresis. These clots developed despite prophylaxis with the platelet inhibitor acetyl salicilic acid (ASA). However, ASA does not inactivate humoral clotting factors.
GM-CSF does not directly induce macrophage procoagulant activity in vitro.2 The in vivo activation of coagulation in the context of GM-CSF shown here and by Stephens et a14 may be explained by indirect mechanisms, such as generation of TNFa and IFNy, that are able to induce a procoagulant state. GM-CSF may in part contribute to the hemostatic dysregulations observed after BMT. days after brnt maximum day of growth factor infusion.
